• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Kellner Group Urges AIM Immunotech Stockholders to Vote for Change

    GLOBENEWSWIRE

    AIM ImmunoTech Publishes Breast Cancer Data From Roswell Park

    GLOBENEWSWIRE

    AIM ImmunoTech Reports Q3 2024 Results, Corporate Update

    GLOBENEWSWIRE

    AIM ImmunoTech to Discuss Q3 2024 Financials on Nov 15

    GLOBENEWSWIRE

    AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit

    GLOBENEWSWIRE

    AIM Immuno Gets US Patent For Ampligen® In Endometriosis Treatment

    GLOBENEWSWIRE

    AIM ImmunoTech Announces $1.26 Million Registered Direct Offering

    GLOBENEWSWIRE

    AIM ImmunoTech To Participate In Virtual Investor CEO Connect

    GLOBENEWSWIRE

    AIM ImmunoTech Reports Positive Data In Pancreatic Cancer Study

    GLOBENEWSWIRE

    AIM ImmunoTech: Ampligen Shows Promise For Post-COVID Fatigue

    GLOBENEWSWIRE

    AIM ImmunoTech`s Ampligen Study For Pancreatic Cancer Published

    GLOBENEWSWIRE

    AIM ImmunoTech Reports Q2 2024 Results and Corporate Update

    GLOBENEWSWIRE

    AIM ImmunoTech To Discuss Q2 2024 Results On August 16

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    GLOBENEWSWIRE

    AIM Reports New Data On Ampligen`s Anti-Tumor Potential In Combo Therapy

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    GLOBENEWSWIRE

    AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

    GLOBENEWSWIRE

    AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

    GLOBENEWSWIRE

    AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

    GLOBENEWSWIRE

    AIM ImmunoTech Reports Q1 2024 Financials, Corporate Update

    GLOBENEWSWIRE

    AIM ImmunoTech Q1 2024 Results Call On May 16

    GLOBENEWSWIRE

    AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

    GLOBENEWSWIRE

    AIM ImmunoTech: Ampligen+Imfinzi Combo Tolerated in Pancreatic Cancer Study

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    GLOBENEWSWIRE

    AIM ImmunoTech Appoints Dr. Lapp As ME/CFS, Long COVID Consultant

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Positive Interim Report Data

    GLOBENEWSWIRE

    AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

    GLOBENEWSWIRE

    AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    GLOBENEWSWIRE

    AIM ImmunoTech to Participate in the Investor Lunch Break: The AIM Opportunity

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Launch of CEO Corner Platform

    GLOBENEWSWIRE

    AIM ImmunoTech Outlines Recent Progress Across Development Pipeline

    GLOBENEWSWIRE

    AIM ImmunoTech Announces First Subject Dosed for Phase 1b/2 Evaluating Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech Reports Positive Results from Phase 2 Study Evaluating Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech Receives Board Authorization for Phase 2 Study of Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Enrollment in the Phase 1b/2 Evaluating Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Open Enrollment for Ph 1b/2 Study Evaluating Ampligen

    GLOBENEWSWIRE

    Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

    BUSINESSWIRE

    AIM ImmunoTech Provides Update Regarding Annual Meeting

    BUSINESSWIRE

    AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen

    GLOBENEWSWIRE

    AIM Completes Treatment of Subject in Phase 2 Study Evaluating Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    AIM Immuno Announces Publication of Data from Phase 1 Study Evaluating Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    AIM Announces Translational Data from Phase 2 Study Evaluating Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

    BUSINESSWIRE

    AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at SITC

    GLOBENEWSWIRE

    AIM ImmunoTech Engages Business Development Firm, Azenova

    GLOBENEWSWIRE

    AIM Immuno Selected to Present at 3rd Annual Marie Sklodowska-Curie Symposium

    GLOBENEWSWIRE

    AIM Announces Report of Data from Roswell Park Comprehensive Cancer Center Study

    GLOBENEWSWIRE

    AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Conference

    GLOBENEWSWIRE

    AIM ImmunoTech Rejects Director Nomination Notice from Activist Group

    BUSINESSWIRE

    AIM ImmunoTech Reports Second Quarter Financial Results

    GLOBENEWSWIRE

    AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    AIM Immuno Announces Completion of Enrollment in Phase 2 Evaluating Ampligen

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.